Literature DB >> 1738142

3-Carboxy-5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, a new prodrug for the antiarthritic agent 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide.

J W Patterson1, P S Cheung, M J Ernest.   

Abstract

The title compound 3-carboxyisoxazole 3 was synthesized by cycloaddition of carbethoxyformonitrile oxide to N-[4-(trifluoromethyl)phenyl]-3-pyrrolidino-2-butenamide (6) with spontaneous elimination of pyrrolidine followed by hydrolysis of the ethyl ester. Compound 3 was shown to be absorbed intact after oral administration to rats. Over 24 h, the compound was metabolized to yield plasma concentrations of the antiinflammatory agent 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (2), similar to those obtained following an equivalent dose of the established prodrug of 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide (1).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738142     DOI: 10.1021/jm00081a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  An experimental and theoretical structural study of 5-amino-3-methylisoxazolo-4-carboxylic acid p-chlorophenylamide.

Authors:  Aneta Jezierska; Jarosław Panek; Stanisław Ryng; Tadeusz Głowiak; Aleksander Koll
Journal:  J Mol Model       Date:  2003-04-05       Impact factor: 1.810

2.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.

Authors:  Margaret A Phillips; Ramesh Gujjar; Nicholas A Malmquist; John White; Farah El Mazouni; Jeffrey Baldwin; Pradipsinh K Rathod
Journal:  J Med Chem       Date:  2008-06-04       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.